Who is sponsoring NCT00103454?

NCT00103454 is sponsored by GlaxoSmithKline.

What condition does NCT00103454 study?

NCT00103454 studies Rhinitis, Allergic, Perennial.

What is the status of NCT00103454?

NCT00103454 is currently COMPLETED.

Last reviewed 2016-09-15 · How we verify

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 4 Weeks in Adult and Adolescent Subjects (12 Years of Age and Older) With Perennial Allergic Rhinitis (PAR)

NCT00103454 Phase 3 COMPLETED

The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with perennial allergic rhinitis (PAR).

Details

Lead sponsor	GlaxoSmithKline
Phase	Phase 3
Status	COMPLETED
Enrolment	288
Start date	2005-01
Completion	2005-05

Conditions

Rhinitis, Allergic, Perennial

Interventions

GW685698X

Primary outcomes

Mean change from baseline over the entire treatment period in daily, reflective total nasal symptom scores. Subjects complete diaries twice daily (every 12 hours) reporting the severity of their PAR symptoms.

Countries

United States, Canada